Effectiveness
Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix
Dynavax; Z-1018; shingles vaccine; Shingrix; vaccine efficacy; side effects; Phase 1/2 trial; immunogenicity
FDA Rejection Derails PTC Therapeutics’ Rare Disease Hopeful
PTC Therapeutics; FDA rejection; vatiquinone; Friedreich’s ataxia; rare disease; efficacy concerns; complete response letter; clinical trial failure
HHS Ends BARDA Funding for Future mRNA Vaccine Development, Citing Efficacy Concerns
mRNA vaccines; BARDA; Robert F. Kennedy Jr.; vaccine efficacy; HHS; COVID-19; flu; project cancellation; public health policy
Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations
Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application
Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price
RFK Jr. claims placebo-controlled vaccine trials are’radical departure’ from past. Experts disagree
Vaccines, placebo-controlled trials, CHARGE Syndrome, experts, Effectiveness, RFK Jr., Policy, Approved, HHS
RFK Jr. promotes measles vaccine as Texas outbreak continues
Vaccines, Texas, Measles, Disease Outbreaks, Measles-Mumps-Rubella Vaccine, Case (situation), RFK gene, Effectiveness, Vaccination, Texas
AstraZeneca’s oral PCSK9 inhibitor halves cholesterol in phase 2 trial
AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
Incyte’s oral HS drug hits study goals, but fails to excite investors
povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission